

DAFTAR PUSTAKA

- Ahmad, Manzoor. Role of Tumor Microenvironment in Breast Cancer and Targeted Therapies. 1st ed. Academic Press; 2022. ISBN: 9780443186967.
- American Joint Committee on Cancer. AJCC Breast Cancer Staging System. 8th ed. Chicago (IL): American College of Surgeons; 2017 [cited 2025 Jul 27]. Available from: <http://www.breastsurgeonsweb.com/wp-content/uploads/downloads/2020/10/AJCC-Breast-Cancer-Staging-System.pdf>
- Aziz Z, Sarhat E, Zaidan Z. Estimation Of Serum Ferroportin And Liver Enzymes In Breast Cancer Patients. Georgian Med News. 2023 Jun;(339):37-41. PMID: 37522771.
- Chander, U. S. K., Vanishree, M., Sulochana, S., & Rowland, M. (2022). Association of Hematological Parameters with Nottingham Histologic Grades of Breast Carcinoma in South Indian Population. *Journal of Pharmaceutical Research International*, 5–11. <https://doi.org/10.9734/jpri/2022/v34i40B36260>
- Ciniselli CM, De Bortoli M, Taverna E, Varinelli L, Pizzamiglio S, Veneroni S, Bonini C, Orlandi R, Verderio P, Bongarzone I. Plasma hepsidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone. *Expert Rev Proteomics*. 2015;12(6):695-701. doi: 10.1586/14789450.2015.1099436. Epub 2015 Oct 23. PMID: 26496240.
- De Domenico I, Ward DM, Kaplan J. Hepsidin and ferroportin: the new players in iron metabolism. *Semin Liver Dis*. 2011 Aug;31(3):272-9. doi: 10.1055/s-0031-1286058. Epub 2011 Sep 7. PMID: 21901657; PMCID: PMC3706197.
- Douba, Z. A., & Ibrahim, R. (2025). Serum Hepsidin Levels in Breast Cancer Patients: Investigating the Correlation to Tumor Stage—A Cross-Sectional Study. *Health Science Reports*, 8(8). <https://doi.org/10.1002/hsr2.71148>
- Ferraz, L. C., Gomes, A. C. da S. F., Mendes, J. T., Moreira, A. C. M., Penna, A. B. R. C., Nogueira, C., Martins Júnior, R. R., & Franca, C. A. da S. (2023). Serum hemoglobin and relation to the staging of patients with breast cancer before the start of radical radiotherapy. *Mastology*, 38–38. <https://doi.org/10.29289/259453942023V33S1038>
- George A, Bobby Z, Dubashi B. Utility of ferritin and inflammatory biomarkers in the diagnosis of different stages of breast cancer. *Saudi Med J*. 2021 Aug;42(8):825- 831. doi: 10.15537/smj.2021.42.8.20210244. PMID: 34344805; PMCID: PMC9195548.
- Harbeck N, Gnant M. Subtypes of Breast Cancer. In: Schwab M, editor. *Encyclopedia of Cancer*. Treasure Island (FL): StatPearls Publishing; 2022. Available from: [NCBI Bookshelf](#)
- Harjianti, T., Fachruddin, A., Minhajat, R., Saleh, S., & Bayu, D. (2023). Interleukine-2 serum level in breast cancer patients. *Caspian Journal of Internal Medicine*, 14(3), 479–484. <https://doi.org/10.22088/cjim.14.3.479>
- Henry M Kuerer, editor. Kuerer's Breast Surgical Oncology. 1st ed. New York: McGraw-Hill; 2010. Available from: AccessSurgery BookID 428

- Hou Y, Zhang S, Wang L, Li J, Qu G, He J, Rong H, Ji H, Liu S. Estrogen regulates iron homeostasis through governing hepatic hepsidin expression via an estrogen response element. *Gene*. 2012 Dec 15;511(2):398-403. doi: 10.1016/j.gene.2012.09.060. Epub 2012 Oct 3. PMID: 23041085.
- ICCP 2025 List Reviewer Page. (2025). *2025 IEEE International Conference on Computational Photography (ICCP)*, xvi–xvi. <https://doi.org/10.1109/ICCP64821.2025.11143830>
- Jerzak KJ, Lohmann AE, Ennis M, Nemeth E, Ganz T, Goodwin PJ. Prognostic associations of plasma hepsidin in women with early breast cancer. *Breast Cancer Res Treat*. 2020 Dec;184(3):927-935. doi: 10.1007/s10549-020-05903-z. Epub 2020 Sep 22. PMID: 32960376; PMCID: PMC7883934.
- Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/414/2018 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara. Jakarta: Kementerian Kesehatan Republik Indonesia; 2018.
- Muhesin, A., Hadi, A. Evaluation of Some Iron Status Markers and Blood Parameters in Women with Breast Cancer. *Egyptian Academic Journal of Biological Sciences. C, Physiology and Molecular Biology*, 2023; 15(2): 667-674. doi: 10.21608/eajbsc.2023.325813
- Mutlu T, Ozoran E, Trabulus DC, Talu CK, Erhan D, Mete M, Guven M. Expression of genes related to iron homeostasis in breast cancer. *Mol Biol Rep*. 2023 Jun;50(6):5157-5163. doi: 10.1007/s11033-023-08433-1. Epub 2023 Apr 29. PMID: 37119411.
- Orlandi R, De Bortoli M, Ciniselli CM, Vaghi E, Caccia D, Garrisi V, Pizzamiglio S, Veneroni S, Bonini C, Agresti R, Daidone MG, Morelli D, Camaschella C, Verderio P, Bongarzone I. Hepsidin and ferritin blood level as noninvasive tools for predicting breast cancer. *Ann Oncol*. 2014 Feb;25(2):352-7. doi: 10.1093/annonc/mdt490. Epub 2013 Dec 3. PMID: 24306042.
- Pan X, Lu Y, Cheng X, Wang J. Hepsidin and ferroportin expression in breast cancer tissue and serum and their relationship with anemia. *Curr Oncol*. 2016 Feb;23(1):e24-6. doi: 10.3747/co.23.2840. Epub 2016 Feb 18. PMID: 26966409; PMCID: PMC4754065.
- Park, C. K., Heo, J., Ham, W. S., Choi, Y.-D., Shin, S. J., & Cho, N. H. (2021). Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma. *Cancer Research and Treatment*, 53(4), 1174–1183. <https://doi.org/10.4143/crt.2021.031>
- PERABOI (Perhimpunan Ahli Bedah Onkologi Indonesia) Panduan Penatalaksanaan Kanker 2020. edisi 2. eds. Djoko Handojo et al. PERABOI (Perhimpunan Ahli Bedah Onkologi Indonesia).
- Pinnix, Z. K., Miller, L. D., Wang, W., D'Agostino, R., Kute, T., Willingham, M. C., Hatcher, H., Tesfay, L., Sui, G., Di, X., Torti, S. V., & Torti, F. M. (2010). Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis. *Science Translational Medicine*, 2(43). <https://doi.org/10.1126/scitranslmed.3001127>
- Pizzamiglio, S.; De Bortoli, M.; Taverna, E.; Signore, M.; Veneroni, S.; Cho, W.C.-s.; Orlandi, R.; Verderio, P.; Bongarzone, I. Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors. *Int. J. Mol. Sci.* 2017, 18, 410. <https://doi.org/10.3390/ijms18020410>

- Pogribny IP. Ferroportin and hepsidin: a new hope in diagnosis, prognosis, and therapy for breast cancer. *Breast Cancer Res.* 2010;12(5):314. doi: 10.1186/bcr2641. Epub 2010 Oct 6. PMID: 21062518; PMCID: PMC3096960.
- R. Elliott and J. Head, "Cancer: Tumor Iron Metabolism, Mitochondrial Dysfunction and Tumor Immunosuppression; "A Tight Partnership—Was Warburg Correct?," *Journal of Cancer Therapy*, Vol. 3 No. 4, 2012, pp. 278-311. doi: 10.4236/jct.2012.34039.
- Raza, U., Sheikh, A., Jamali, S. N., Turab, M., Zaidi, S. A., & Jawaid, H. (2020). Post-treatment Hematological Variations and the Role of Hemoglobin as a Predictor of Disease-free Survival in Stage 2 Breast Cancer Patients. *Cureus*. <https://doi.org/10.7759/cureus.7259>
- Shao X, Cao F, Tao M. The clinical value of hepsidin in breast cancer and its bone metastasis. *Annals of Clinical & Laboratory Science*. 2017 Mar 1;47(2):120-8.
- Townsend, Courtney, Daniel Beauchamp, B. Marks Evers, and Kenneth L Mattox. 2022. 2 *Angewandte Chemie International Edition*, 6(11), 951–952. Sabiston Textbook of Surgery Yhe Biological Basis of Modern Surgical Practice. 21st edition. Elsevier Inc. Ward DM, Kaplan J. Ferroportin-mediated iron transport: expression and regulation. *Biochim BiophysActa*. 2012 Sep;1823(9):1426-33. doi: 10.1016/j.bbamcr.2012.03.004. Epub 2012 Mar 13. PMID: 22440327; PMCID: PMC3718258.
- Ubayawansa, B., Shilpage, S., & De Silva, K. (2021). Prevalence of molecular subtypes of breast cancer: Experience in a tertiary care cancer centre in Sri Lanka. *Anuradhapura Medical Journal*, 15(1), 9. <https://doi.org/10.4038/amj.v15i1.7697>
- Xu Y, Alfaro-Magallanes VM, Babitt JL. Physiological and pathophysiological mechanisms of hepsidin regulation: clinical implications for iron disorders. *Br J Haematol*. 2021 Jun;193(5):882-893. doi: 10.1111/bjh.17252. Epub 2020 Dec 14. PMID: 33316086; PMCID: PMC8164969.
- Yalovenko TM, Todor IM, Lukianova NY, Chekhun VF. Hepsidin as a possible marker in determination of malignancy degree and sensitivity of breast cancer cells to cytostatic drugs. *Exp Oncol*. 2016 Jun;38(2):84-8. PMID: 27356575.
- Zhu, Haoling, and Başak E. Doğan. 2021. "American Joint Committee on Cancer's Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians." *European Journal of Breast Health* 17(3): 234–38.